WESTFORD, Mass., April 13 /PRNewswire-FirstCall/ -- Cynosure, Inc. , a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, announced today that it has received pre-market approval from the Korea Food and Drug Administration (KFDA) for its Cynergy vascular laser system with MultiPlex(TM) technology.
"We are excited about the opportunity to sell our leading-edge system in the emerging South Korean market," said Cynosure Chief Executive Officer Michael R. Davin. "The Cynergy workstation with MultiPlex technology represents our second major product introduction in Korea this year.
"The Cynergy workstation with MultiPlex technology marks an innovative development in the treatment of dermatological vascular conditions through the use of laser-based technology," Davin said. "This system is the culmination of significant research and development efforts internally and collaboratively with physicians at the forefront of their specialties."
The Cynergy workstation with MultiPlex technology is the first system to enable the rapid sequential emission of two wavelengths from the same fiber optic -- a pulse-dye laser and an Nd:YAG laser -- with a short time delay between the two pulses. The time delay increases safety and efficacy of laser treatment.
In clinical studies, treatments using the Cynergy workstation with MultiPlex technology have shown an increased depth of penetration of energy and improved effectiveness in treating portwine stains, and improved outcomes for facial and leg telangiectasia when compared to treatments using a pulse-dye laser or an Nd:YAG laser individually. Previously, the limited efficacy of either a pulse-dye laser or an Nd:YAG laser in the treatment of portwine stains, hemangiomas and spider veins made those conditions resistant to treatment. Cynosure's MultiPlex technology, however, allows for customized, patient-specific treatments using these two lasers together, which improves efficacy, decreases treatment lengths and shortens patient downtime.
Cynosure's Cynergy workstation with MultiPlex technology is distributed in South Korea by OrientMG. "As the only dual-wavelength, single fiber optic system available in the Asia Pacific marketplace, the Cynergy workstation with MultiPlex technology provides a distinct competitive advantage for our customers," said Douglas Kim, president of OrientMG. "This technology enables our customers to offer a broader array of treatment options for vascular lesions, hair removal and skin rejuvenation."
About OrientMG
OrientMG, located in Seoul, Korea, is the exclusive Korean distributor of Cynosure, Inc. A full-service medical device supplier to the dermatology, plastic surgery, primary care and dentistry markets, OrientMG has an extensive network of product and service representatives throughout South Korea.
For more information, contact OrientMG at +82 2 546 7577, or log onto http://www.orientmg.com.
About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse-dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991.
For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosurelaser.com.
Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the future use and market acceptance of the Cynergy workstation with MutiPlex technology, the markets in which Cynosure's products are sold, and other statements containing the words "believes," "anticipates," "plans," "expects," "will," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including our history of operating losses, our reliance on sole source suppliers, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's Annual Report on Form 10-K filed with the SEC. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.
Contact: Timothy Baker
800-886-2966 tbaker@cynosurelaser.com
Cynosure, Inc.CONTACT: Timothy Baker for Cynosure, +1-800-886-2966,tbaker@cynosurelaser.com
